All News
Filter News
Found 2,438 articles
-
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
1/2/2018
Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.
-
The total capital raised by Flagship to fuel its institutional innovation and venture creation platform now exceeds $2.3B.
-
Moderna Publishes Preclinical Data in Cell Reports on mRNA Therapeutic to Treat Rare Liver Disease Methylmalonic Acidemia (MMA), A Disorder of Organic Acid Metabolism
12/20/2017
Moderna announced the publication of preclinical data supporting its first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA), a serious and often life-threatening organic acidemia.
-
Indiana University School of Medicine Researchers Identify First Brain Training Exercise Positively Linked to Dementia Prevention
11/17/2017
The cognitive training, called speed of processing, showed benefits up to 10 years after study participants underwent the mental exercise program, said Frederick W. Unverzagt, PhD, professor of psychiatry at Indiana University School of Medicine.
-
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
-
Evox Therapeutics Appoints Antonin de Fougerolles as Chief Executive Officer
11/13/2017
Experienced life sciences executive with strong history of successful advancement of novel drug platforms and pipeline development [13-November-2017] OXFORD, England, November 13, 2017 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr Antonin &quo
-
Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer
11/13/2017
Dr. Springhorn will hold broad management responsibility for business development and strategic planning.
-
Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.
-
5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration
11/6/2017
The International mRNA Health Conference, the premier meeting destination for professionals and academics in the field of mRNA drugs, celebrated the success of its 5th annual event held in Berlin, Germany on November 1–2.
-
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
-
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
-
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.
-
3 More Moderna R&D Execs Quietly Step Down
10/18/2017
So this year, Moderna has lost the head of its cancer division, its top lawyer, and its chief business officer. -
Stephen Berenson Joins Moderna’s Board Of Directors
10/10/2017
-
Avacta Group Initiates Gene Therapy Research Collaboration With FIT Biotech Oy
10/9/2017
-
Avacta Group Preliminary Results for the Year Ending 31 July 2017
10/4/2017
-
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
9/29/2017
-
Moderna Announces Publication In Molecular Therapy Characterizing Potent Immune Response Generated By Its mRNA Prophylactic Vaccines
9/26/2017
-
NeuralStem Announces The Appointment Of Two New Members To The Board Of Directors
9/26/2017
-
Dr. Marie-Paule Kieny Appointed To The Human Vaccines Project Board Of Directors
9/26/2017